FDA Novel Drugs
Generic Name: narsoplimab-wuug
- Brand Name: YARTEMLEA
- Drug Class: MASP-2
- Sponsor by: Omeros Corporation
- Approval Date: 23/12/2025
On December 23, 2025, the U.S. Food and Drug Administration (FDA) approved Yartemlea (narsoplimab-wuug), a novel MASP-2 inhibitor developed by Omeros Corporation. This marks a significant regulatory milestone as Yartemlea
